Jan 17 (Reuters) - Bioline Rx Ltd:
* BIOLINERX ANNOUNCES PARTIAL MONOTHERAPY RESULTS FROM PHASE 2A COMBAT STUDY IN PANCREATIC CANCER
* BIOLINE RX LTD - DATA TO BE PRESENTED AT UPCOMING ASCO-GI CONFERENCE; TOPLINE CLINICAL RESULTS EXPECTED BY H2 2018 AS PLANNED
* BIOLINE RX LTD - BL-8040 MONOTHERAPY RESULTED IN INCREASED INFILTRATION OF T CELLS INTO TUMOR
* BIOLINE RX LTD - PARTIAL RESULTS FROM BL-8040 MONOTHERAPY PORTION OF COMBAT TRIAL SHOW THAT BL-8040 WAS SAFE AND WELL-TOLERATED Source text for Eikon: Further company coverage:
 